The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Elevated micro RNA‐34a in obesity reduces NAD+ levels and SIRT 1 activity by directly targeting NAMPT
Open accessAbstract
Summary: SIRT1 is an NAD+‐dependent deacetylase that is implicated in prevention of many age‐related diseases including metabolic disorders. As SIRT1 deacetylase activity is dependent on NAD+ levels and the development of compounds that directly activate SIRT1 has been controversial, indirectly activating SIRT1 through enhancing NAD+ bioavailability has received increasing attention. NAD+ levels are reduced in obesity and the aged, but the underlying mechanisms remain unclear. We recently showed that hepatic microRNA‐34a (miR‐34a), which is elevated in obesity, directly targets and decreases SIRT1 expression. Here, we further show that miR‐34a reduces NAD+ levels and SIRT1 activity by targeting NAMPT, the rate‐limiting enzyme for NAD+ biosynthesis. A functional binding site for miR‐34a is present in the 3′ UTR of NAMPT mRNA. Hepatic overexpression of miR‐34a reduced NAMPT/NAD+ levels, increased acetylation of the SIRT1 target transcriptional regulators, PGC‐1α, SREBP‐1c, FXR, and NF‐κB, and resulted in obesity‐mimetic outcomes. The decreased NAMPT/NAD+ levels were independent of miR‐34a effects on SIRT1 levels as they were also observed in SIRT1 liver‐specific knockout mice. Further, the miR‐34a‐mediated decreases were reversed by treatment with the NAD+ intermediate, nicotinamide mononucleotide. Conversely, antagonism of miR‐34a in diet‐induced obese mice restored NAMPT/NAD+ levels and alleviated steatosis, inflammation, and glucose intolerance. Anti‐miR‐34a‐mediated increases in NAD+ levels were attenuated when NAMPT was downregulated. Our findings reveal a novel function of miR‐34a in reducing both SIRT1 expression and activity in obesity. The miR‐34a/NAMPT axis presents a potential target for treating obesity‐ and aging‐related diseases involving SIRT1 dysfunction like steatosis and type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Resveratrol improves health and survival of mice on a high-calorie diet
Baur, J. A., Pearson, K. J., Price, N. L., Jamieson, H. A., Lerin, C., Kalra, A., Prabhu, V. V., Allard, J. S., Lopez-Lluch, G., Lewis, K., et al. (2006) · Nature · doi:10.1038/nature05354 · Cited by 4,290
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 8×
“As NAD+ is required for SIRT1-mediated deacetylation (Imai et al., 2000; Imai, 2011) and NAD+ levels are decreased by miR-34a, we next asked whether SIRT1 deacetylase activity is also affected by measuring acetylation levels of the known SIRT1 target transcriptional regulators, PGC-1a, SREBP-1c,…”
BackgroundInfluentialAMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
Rodgers, J. T., Lerin, C., Haas, W., Gygi, S. P., Spiegelman, B. M., & Puigserver, P. (2005) · Nature · doi:10.1038/nature03354 · Cited by 3,160
Sirtuins as regulators of metabolism and healthspan
Houtkooper, R. H., Pirinen, E., & Auwerx, J. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3293 · Cited by 2,008
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes
Milne, J. C., Lambert, P. D., Schenk, S., Carney, D. P., Smith, J. J., Gagne, D. J., Jin, L., Boss, O., Perni, R. B., Vu, C. B., et al. (2007) · Nature · doi:10.1038/nature06261 · Cited by 1,707 · cited 1×
“In addition to resveratrol, SIRT1 is also activated by synthetic compounds, including SRT1720 (Milne et al., 2007; Feige et al., 2008).”
BackgroundCantó, C., Houtkooper, R. H., Pirinen, E., Youn, D. Y., Oosterveer, M. H., Cen, Y., Fernandez-Marcos, P. J., Yamamoto, H., Andreux, P. A., Cettour-Rose, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.04.022 · Cited by 1,238 · cited 2×
“Recent studies have shown that treatment with NAD+ intermediates or precursors that increase cellular NAD+ levels, including NMN or NR, counteracts obesity and improves insulin sensitivity in diabetic obese mice (Bai et al., 2011; Yoshino et al., 2011; Canto et al., 2012).”
BackgroundMicroRNAs in metabolism and metabolic disorders
Rottiers, V., & Näär, A. M. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3313 · Cited by 1,156
MicroRNAs 103 and 107 regulate insulin sensitivity
Trajkovski, M., Hausser, J., Soutschek, J., Bhat, B., Akin, A., Zavolan, M., Heim, M. H., & Stoffel, M. (2011) · Nature · doi:10.1038/nature10112 · Cited by 1,000
Cited by
NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR
Yoshino, J., Baur, J. A., & Imai, S.-I. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.11.002 · Cited by 1,061
NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential
Xie, N., Zhang, L., Gao, W., Huang, C., Huber, P. E., Zhou, X., Li, C., Shen, G., & Zou, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00311-7 · Cited by 1,052
Yuan, T., Yang, T., Chen, H., Fu, D., Hu, Y., Wang, J., Yuan, Q., Yu, H., Xu, W., & Xie, X. (2019) · Redox Biology · doi:10.1016/j.redox.2018.09.025 · Cited by 743
Physiological and pathophysiological roles of NAMPT and NAD metabolism.
Garten, A., Schuster, S., Penke, M., Gorski, T., de Giorgis, T., & Kiess, W. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.117 · Cited by 708
Molecular and Cellular Mechanisms of Cardiovascular Disorders in Diabetes
Shah, M. S., & Brownlee, M. (2016) · Circulation Research · doi:10.1161/circresaha.116.306923 · Cited by 602
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 544
NAD+ metabolism, stemness, the immune response, and cancer
Navas, L. E., & Carnero, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 517
Pan, Y., Hui, X., Hoo, R. L. C., Ye, D., Chan, C. Y. C., Feng, T., Wang, Y., Lam, K. S. L., & Xu, A. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123069 · Cited by 493
The p53/miR-34 axis in development and disease
Rokavec, M., Li, H., Jiang, L., & Hermeking, H. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mju003 · Cited by 354
Keating, S. T., & El-Osta, A. (2015) · Circulation Research · doi:10.1161/circresaha.116.303936 · Cited by 317
Regulation of SIRT1 in aging: Roles in mitochondrial function and biogenesis
Yuan, Y., Cruzat, V. F., Newsholme, P., Cheng, J., Chen, Y., & Lu, Y. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.02.003 · Cited by 299
A metabolic stress-inducible miR-34a-HNF4α pathway regulates lipid and lipoprotein metabolism
Xu, Y., Zalzala, M., Xu, J., Li, Y., Yin, L., & Zhang, Y. (2015) · Nature Communications · doi:10.1038/ncomms8466 · Cited by 277
NAD metabolism: Implications in aging and longevity
Yaku, K., Okabe, K., & Nakagawa, T. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.05.006 · Cited by 269
Ding, J., Li, M., Wan, X., Jin, X., Chen, S., Yu, C., & Li, Y. (2015) · Scientific Reports · doi:10.1038/srep13729 · Cited by 261
Obesity May Accelerate the Aging Process
Salvestrini, V., Sell, C., & Lorenzini, A. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00266 · Cited by 260
Implications of altered NAD metabolism in metabolic disorders
Okabe, K., Yaku, K., Tobe, K., & Nakagawa, T. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0527-8 · Cited by 223
Chen, X., Luo, Y., Zhu, Q., Zhang, J., Huang, H., Kan, Y., Li, D., Xu, M., Liu, S., Li, J., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00612-4 · Cited by 174
A dysregulated acetyl/SUMO switch of FXR promotes hepatic inflammation in obesity
Kim, D., Xiao, Z., Kwon, S., Sun, X., Ryerson, D., Tkac, D., Ma, P., Wu, S., Chiang, C., Zhou, E., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201489527 · Cited by 126
Self-citationChen, J., Sysol, J. R., Singla, S., Zhao, S., Yamamura, A., Valdez-Jasso, D., Abbasi, T., Shioura, K. M., Sahni, S., Reddy, V., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024557 · Cited by 86
Ruggieri, S., Orsomando, G., Sorci, L., & Raffaelli, N. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.02.021 · Cited by 71
MicroRNAs, Long Non-Coding RNAs, and Circular RNAs in the Redox Control of Cell Senescence
Lettieri-Barbato, D., Aquilano, K., Punziano, C., Minopoli, G., & Faraonio, R. (2022) · Antioxidants · doi:10.3390/antiox11030480 · Cited by 51
Recent insights into the pathogenesis and therapeutic targets of chronic liver diseases
Wen, Y., Ma, L., & Ju, C. (2023) · eGastroenterology · doi:10.1136/egastro-2023-100020 · Cited by 31
Lai, X., Huang, S., Lin, S., Pu, L., Wang, Y., Lin, Y., Huang, W., & Wang, Z. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02688-w · Cited by 26
Schwartz, S. S., & Amrom, D. (2023) · Current Diabetes Reviews · doi:10.2174/1573399818666220422085016 · Cited by 20
Andonotopo, W., Bachnas, M. A., Dewantiningrum, J., Adi Pramono, M. B., Sulistyowati, S., Hariyasa Sanjaya, I. N., Stanojevic, M., & Kurjak, A. (2026) · Journal of Perinatal Medicine · doi:10.1515/jpm-2025-0289 · Cited by 15
Metadata
- Authors
- Choi, S., Fu, T., Seok, S., Kim, D., Yu, E., Lee, K., Kang, Y., Li, X., Kemper, B., & Kemper, J. K.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2013-08-11
- Volume
- 12
- Issue
- 6
- Pages
- 1062-1072
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W1975400918
- Cited by
- 249
- References
- 18
- FWCI
- 8.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.